 SAN DIEGO, March 11, 2021 GLOBE NEWSWIRE -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of 16.00 per share. The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be 80.0 million. 